Which has higher earnings & valuation, NTRA or ABVX?

Natera has higher revenue and earnings than Abivax. Natera is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.00 -$208.16M -$1.63 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is NTRA or ABVX more profitable?

Abivax has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.82% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.82% -8.19% Abivax N/A -99.02% -70.26%

Does the media prefer NTRA or ABVX?

In the previous week, Natera had 33 more articles in the media than Abivax. MarketBeat recorded 38 mentions for Natera and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Natera's score of 0.65 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 19 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABVX or RVMD more profitable?

Abivax's return on equity of -99.02% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Revolution Medicines N/A -102.61% -70.72%

Does the media favor ABVX or RVMD?

In the previous week, Revolution Medicines had 17 more articles in the media than Abivax. MarketBeat recorded 22 mentions for Revolution Medicines and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Revolution Medicines' score of 0.63 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings and valuation, BIIB or ABVX?

Biogen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.06 $1.29B $5.65 36.80 Abivax N/A N/A -$380.27M -$5.21 N/A

Is BIIB or ABVX more profitable?

Biogen has a net margin of 8.32% compared to Abivax's net margin of 0.00%. Biogen's return on equity of 11.18% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Abivax N/A -99.02% -70.26%

Does the media refer more to BIIB or ABVX?

In the previous week, Biogen had 20 more articles in the media than Abivax. MarketBeat recorded 25 mentions for Biogen and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Biogen's score of 0.98 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 15 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABVX or ALNY?

In the previous week, Alnylam Pharmaceuticals had 34 more articles in the media than Abivax. MarketBeat recorded 39 mentions for Alnylam Pharmaceuticals and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Alnylam Pharmaceuticals' score of 0.00 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 6 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ABVX or INSM?

Abivax has higher earnings, but lower revenue than Insmed. Abivax is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Insmed $606.42M 46.86 -$1.28B -$5.75 N/A

Is ABVX or INSM more profitable?

Abivax has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Abivax's return on equity of -99.02% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Insmed -76.94% -122.43% -43.65%

Does the media prefer ABVX or INSM?

In the previous week, Insmed had 19 more articles in the media than Abivax. MarketBeat recorded 24 mentions for Insmed and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Insmed's score of 0.97 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Abivax (ABVX) Competitors

$130.93 +0.93 (+0.72%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$131.09 +0.16 (+0.12%)

As of 08/7/2026 06:40 PM Eastern

Compare

ABVX vs. NTRA, RVMD, BIIB, ALNY, and INSM

Should you buy Abivax stock or one of its competitors? MarketBeat compares Abivax with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abivax include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Insmed (INSM). These companies are all part of the "biotechnology" industry.

How does Abivax compare to Natera?

Natera (NASDAQ:NTRA) and Abivax (NASDAQ:ABVX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Natera has higher revenue and earnings than Abivax. Natera is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.00	-$208.16M	-$1.63	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

In the previous week, Natera had 33 more articles in the media than Abivax. MarketBeat recorded 38 mentions for Natera and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Natera's score of 0.65 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	19 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Abivax	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.82% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.82%	-8.19%
Abivax	N/A	-99.02%	-70.26%

Natera has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Abivax has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Natera currently has a consensus price target of $299.65, suggesting a potential downside of 6.97%. Abivax has a consensus price target of $156.50, suggesting a potential upside of 19.53%. Given Abivax's stronger consensus rating and higher possible upside, analysts clearly believe Abivax is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

99.9% of Natera shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Natera beats Abivax on 11 of the 16 factors compared between the two stocks.

How does Abivax compare to Revolution Medicines?

Abivax (NASDAQ:ABVX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Abivax has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$7.07	N/A

Abivax's return on equity of -99.02% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Revolution Medicines	N/A	-102.61%	-70.72%

47.9% of Abivax shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abivax has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Abivax presently has a consensus price target of $156.50, indicating a potential upside of 19.53%. Revolution Medicines has a consensus price target of $153.05, indicating a potential downside of 25.39%. Given Abivax's higher possible upside, analysts clearly believe Abivax is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

In the previous week, Revolution Medicines had 17 more articles in the media than Abivax. MarketBeat recorded 22 mentions for Revolution Medicines and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Revolution Medicines' score of 0.63 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Abivax compare to Biogen?

Biogen (NASDAQ:BIIB) and Abivax (NASDAQ:ABVX) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Biogen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.06	$1.29B	$5.65	36.80
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Biogen has a net margin of 8.32% compared to Abivax's net margin of 0.00%. Biogen's return on equity of 11.18% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Abivax	N/A	-99.02%	-70.26%

87.9% of Biogen shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biogen presently has a consensus target price of $224.61, indicating a potential upside of 8.02%. Abivax has a consensus target price of $156.50, indicating a potential upside of 19.53%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Biogen had 20 more articles in the media than Abivax. MarketBeat recorded 25 mentions for Biogen and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Biogen's score of 0.98 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	15 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Abivax on 12 of the 16 factors compared between the two stocks.

How does Abivax compare to Alnylam Pharmaceuticals?

Abivax (NASDAQ:ABVX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Abivax has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

In the previous week, Alnylam Pharmaceuticals had 34 more articles in the media than Abivax. MarketBeat recorded 39 mentions for Alnylam Pharmaceuticals and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Alnylam Pharmaceuticals' score of 0.00 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	6 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abivax currently has a consensus target price of $156.50, suggesting a potential upside of 19.53%. Alnylam Pharmaceuticals has a consensus target price of $396.72, suggesting a potential upside of 80.98%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

Alnylam Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Alnylam Pharmaceuticals	$4.80B	6.11	$313.75M	$5.38	40.74

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Abivax's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Summary

Alnylam Pharmaceuticals beats Abivax on 14 of the 16 factors compared between the two stocks.

How does Abivax compare to Insmed?

Abivax (NASDAQ:ABVX) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Abivax currently has a consensus price target of $156.50, suggesting a potential upside of 19.53%. Insmed has a consensus price target of $205.26, suggesting a potential upside of 56.57%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

47.9% of Abivax shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abivax has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Abivax's return on equity of -99.02% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Insmed	-76.94%	-122.43%	-43.65%

Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

In the previous week, Insmed had 19 more articles in the media than Abivax. MarketBeat recorded 24 mentions for Insmed and 5 mentions for Abivax. Abivax's average media sentiment score of 1.37 beat Insmed's score of 0.97 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has higher earnings, but lower revenue than Insmed. Abivax is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Insmed	$606.42M	46.86	-$1.28B	-$5.75	N/A

Summary

Abivax and Insmed tied by winning 8 of the 16 factors compared between the two stocks.

Get Abivax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVX vs. The Competition

Export

Metric	Abivax	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.34B	$3.62B	$6.93B	$12.87B
Dividend Yield	N/A	3.77%	2.59%	9.91%
P/E Ratio	-25.13	9.03	271.39	25.24
Price / Sales	N/A	1,274.65	598.32	98.55
Price / Cash	N/A	98.58	71.46	49.72
Price / Book	19.93	18.10	13.25	6.22
Net Income	-$380.27M	-$13.25M	$3.45B	$342.66M
7 Day Performance	4.81%	6.24%	4.67%	4.41%
1 Month Performance	-5.49%	-2.70%	-0.79%	-0.28%
1 Year Performance	86.70%	61.17%	76.94%	22.60%

Abivax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVX Abivax	3.2652 of 5 stars	$130.93 +0.7%	$156.50 +19.5%	+87.0%	$11.34B	N/A	N/A	61	Positive News
NTRA Natera	2.93 of 5 stars	$316.24 +19.2%	$273.11 -13.6%	+128.3%	$45.17B	$2.50B	N/A	6,140	Trending News Earnings Report Analyst Forecast Insider Trade Gap Up
RVMD Revolution Medicines	1.6093 of 5 stars	$197.69 -0.1%	$153.05 -22.6%	+487.0%	$41.98B	$11.58M	N/A	250	Earnings Report Analyst Forecast
BIIB Biogen	3.9124 of 5 stars	$206.60 +0.2%	$224.61 +8.7%	+62.8%	$30.51B	$9.89B	36.55	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.6437 of 5 stars	$215.60 -0.2%	$396.72 +84.0%	-49.6%	$28.80B	$3.71B	40.01	2,770	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVX) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Competitors